Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Invested Capital (2016 - 2025)

Historic Invested Capital for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $126.6 million.

  • Enanta Pharmaceuticals' Invested Capital rose 1321.37% to $126.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $126.6 million, marking a year-over-year increase of 1321.37%. This contributed to the annual value of $64.7 million for FY2025, which is 4975.93% down from last year.
  • Enanta Pharmaceuticals' Invested Capital amounted to $126.6 million in Q4 2025, which was up 1321.37% from $64.7 million recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Invested Capital registered a high of $436.0 million during Q1 2021, and its lowest value of $64.7 million during Q3 2025.
  • For the 5-year period, Enanta Pharmaceuticals' Invested Capital averaged around $239.6 million, with its median value being $227.3 million (2023).
  • Over the last 5 years, Enanta Pharmaceuticals' Invested Capital had its largest YoY gain of 1321.37% in 2025, and its largest YoY loss of 4975.93% in 2025.
  • Enanta Pharmaceuticals' Invested Capital (Quarter) stood at $384.4 million in 2021, then dropped by 21.74% to $300.8 million in 2022, then crashed by 36.22% to $191.9 million in 2023, then crashed by 41.73% to $111.8 million in 2024, then increased by 13.21% to $126.6 million in 2025.
  • Its Invested Capital stands at $126.6 million for Q4 2025, versus $64.7 million for Q3 2025 and $79.3 million for Q2 2025.